Get started
Author

Greg Wiseman

A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
2003 · Andrew M Scott, Greg Wiseman, et al. · PubMed · 438
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
2004 · Leo I. Gordon, Arturo Molina, et al. · Blood · 189
PDF
Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma
2004 · Leo I. Gordon, Thomas Witzig, et al. · Clinical Lymphoma · 124
Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study
2013 · Al B. Benson, Jean-Francois Geschwind, et al. · European Journal of Cancer · 87
Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse
2013 · A. Robinson, M. Hankins, et al. · Alimentary Pharmacology & Therapeutics · 50
PDF
Radiation exposure is very low to patient family members following Zevalin yttrium-90 anti-CD20 monoclonal antibody therapy for lymphoma
2001 · Greg Wiseman · European Journal of Nuclear Medicine and Molecular Imaging · 24
Fibrinogen Early In Severe paediatric Trauma studY (FEISTY junior): protocol for a randomised controlled trial
2022 · Shane George, Elizabeth Wake, et al. · BMJ Open · 7
PDF
Management of Pediatric Thoracic Empyema in the North Queensland Region of Australia and Impact of a Local Evidence-based Treatment Guideline
2022 · Gautam, Anil, Wiseman, Gregory, et al. · ResearchOnline at James Cook University (James Cook University) · 4
PTU-066 A Model To Assess The Cost Of Flare In Ulcerative Colitis (uc) To The Nhs
2014 · A Bassi, K Tolley, et al. · Gut · 1
PDF
Abstract P-427: MANAGEMENT AND OUTCOMES OF COMMUNITY ACQUIRED PAEDIATRIC THORACIC EMPYEMA (pTE) IN THE NORTH QUEENSLAND REGION OF AUSTRALIA: A 10 YEAR SINGLE CENTRE EXPERIENCE
2018 · A. Gautam, G. Wiseman, et al. · Pediatric Critical Care Medicine
PTH-119 Understanding symptom burden and attitudes in patients with irritable bowel syndrome with diarrhoea: results from a patient survey
2017 · H Törnblom, A Emmanuel, et al.
Letter: switches of 5‐aminosalicylates in ulcerative colitis, risk of relapse and ascertainment bias – authors’ reply
2014 · A. Robinson, M. Hankins, et al. · Alimentary Pharmacology & Therapeutics
Commentary: 5-ASA switches in IBD, adherence and flares - authors' reply
2013 · A. Robinson, M. Hankins, et al. · Alimentary Pharmacology & Therapeutics
PDF
P427 Non-adherence and 5-ASA switches in stable IBD patients are associated with increased risk of relapse
2013 · A. Robinson, M. Hankins, et al. · Journal of Crohn s and Colitis
PDF
P413 Persistence with 5-ASA therapy in the UK: a matched sample study
2013 · A. Robinson, M. Hankins, et al. · Journal of Crohn s and Colitis
PDF
Abstract No. 1: Safety, response and survival outcomes of Y90 radioembolization for liver metastases: Results from a 151 patient investigational device exemption multi-institutional study
2011 · A. Benson, M.F. Mulcahy, et al. · Journal of Vascular and Interventional Radiology
PDF
Works count: 16
Citation count: 924
H-index: 7
I10-index: 6
Year
Topic
Type